Research: New Blood Test May Detect Early Stage Lung Cancer
In most cases, non small cell lung carcinoma becomes incurable as it is not diagnosed until reached an advanced level. At the later stages of lung cancer, it gets difficult to cure the disease. To help improve the survival rates, researchers are working towards developing blood test to detect lung cancer at an early stage. The study has been published in The Journal of Molecular Diagnostics. It has described a new technology called electric field-induced release and measurement (EFIRM). It is capable of detecting two epidermal growth factor receptor (EGFR) mutations associated with lung cancer in the blood of non-small cell lung carcinoma patients in the early stage. This platform is relatively inexpensive and capable of high-throughput testing. The five-year survival for patients diagnosed with NSCLC is less than 10%. The ability to diagnose NSCLC in stages 1 and 2 could significantly reduce the mortality from NSCLC. "The revolutionary EFIRM technology is the most exciting development